• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    5/5/23 1:31:32 PM ET
    $APTX
    $BIOL
    $DMTK
    $ELOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $APTX alert in real time by email

    Gainers

    • Nanobiotix (NASDAQ:NBTX) shares rose 238.9% to $6.88 during Friday's regular session. As of 13:30 EST, Nanobiotix's stock is trading at a volume of 34.0 million, which is 1334582.0% of its average full-day volume over the last 100 days. The company's market cap stands at $242.3 million.
    • Owens & Minor (NYSE:OMI) shares moved upwards by 35.71% to $18.39. The current volume of 1.5 million shares is 150.0% of Owens & Minor's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $1.4 billion. The company's, Q1 earnings came out today.
    • ImmunityBio (NASDAQ:IBRX) stock rose 35.14% to $5.23. Trading volume for this security as of 13:30 EST is 14.4 million, which is 327.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 billion.
    • Star Equity Hldgs (NASDAQ:STRR) shares increased by 30.79% to $0.9. The current volume of 3.2 million shares is 9586.5% of Star Equity Hldgs's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $13.6 million.
    • HOOKIPA Pharma (NASDAQ:HOOK) stock rose 24.35% to $1.69. Trading volume for HOOKIPA Pharma's stock is 1.4 million as of 13:30 EST. This is 371.2% of its average full-day volume over the last 100 days. The company's market cap stands at $92.5 million.
    • Puma Biotechnology (NASDAQ:PBYI) shares increased by 21.91% to $3.18. Puma Biotechnology's stock is trading at a volume of 564.8K shares as of 13:30 EST. This is 183.0% of its average full-day volume over the last 100 days. The company's market cap stands at $148.5 million. As per the press release, Q1 earnings came out yesterday.

    Losers

    • Soligenix (NASDAQ:SNGX) stock declined by 48.9% to $1.17 during Friday's regular session. As of 13:30 EST, this security is trading at a volume of 6.7 million shares, making up 1084.8% of its average full-day volume over the last 100 days. The company's market cap stands at $3.4 million.
    • Aptinyx (NASDAQ:APTX) stock declined by 31.05% to $0.08. Aptinyx's stock is trading at a volume of 25.1 million shares as of 13:30 EST. This is 706.7% of its average full-day volume over the last 100 days. The company's market cap stands at $5.5 million.
    • DermTech (NASDAQ:DMTK) shares decreased by 28.89% to $2.24. As of 13:30 EST, DermTech's stock is trading at a volume of 1.8 million, which is 452.9% of its average full-day volume over the last 100 days. The company's market cap stands at $69.6 million. The company's, Q1 earnings came out yesterday.
    • GlucoTrack (NASDAQ:GCTK) stock decreased by 21.43% to $0.5. As of 13:30 EST, GlucoTrack's stock is trading at a volume of 773.6K, which is 26.9% of its average full-day volume over the last 100 days. The company's market cap stands at $10.3 million.
    • Biolase (NASDAQ:BIOL) stock declined by 21.28% to $0.21. Trading volume for this security as of 13:30 EST is 1.2 million, which is 125.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.5 million.
    • Eloxx Pharmaceuticals (NASDAQ:ELOX) shares fell 19.49% to $5.0. The company's market cap stands at $10.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APTX
    $BIOL
    $DMTK
    $ELOX

    CompanyDatePrice TargetRatingAnalyst
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    Owens & Minor Inc.
    $OMI
    11/3/2025$4.00Buy → Neutral
    UBS
    ImmunityBio Inc.
    $IBRX
    5/20/2025$5.00Neutral → Overweight
    Piper Sandler
    ImmunityBio Inc.
    $IBRX
    3/6/2025$8.00Buy
    H.C. Wainwright
    ImmunityBio Inc.
    $IBRX
    1/10/2025$6.00Buy
    BTIG Research
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    Nanobiotix S.A.
    $NBTX
    8/28/2024$12.00Buy
    Guggenheim
    More analyst ratings

    $APTX
    $BIOL
    $DMTK
    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Simon Barry J. sold $900,788 worth of shares (75,000 units at $12.01), decreasing direct ownership by 3% to 2,850,821 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/26/26 8:12:26 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Selecky Christobel exercised 25,000 shares at a strike of $2.98 and sold $250,000 worth of shares (25,000 units at $10.00) (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:58 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Soon-Shiong Patrick converted options into 114,329 shares and covered exercise/tax liability with 58,170 shares, increasing direct ownership by 0.19% to 29,757,911 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:07 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APTX
    $BIOL
    $DMTK
    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Owens & Minor downgraded by UBS with a new price target

    UBS downgraded Owens & Minor from Buy to Neutral and set a new price target of $4.00

    11/3/25 9:08:29 AM ET
    $OMI
    Medical Specialities
    Health Care

    ImmunityBio upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded ImmunityBio from Neutral to Overweight and set a new price target of $5.00

    5/20/25 8:01:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APTX
    $BIOL
    $DMTK
    $ELOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Eberwein Jeffrey E. sold $39,794 worth of Series A Preferred Stock (4,365 units at $9.12) and bought $81,503 worth of shares (7,268 units at $11.21), increasing direct ownership by 27% to 1,007,824 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/31/25 5:02:24 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Eberwein Jeffrey E. sold $173,974 worth of Series A Preferred Stock (18,635 units at $9.34) and bought $109,212 worth of shares (9,709 units at $11.25), increasing direct ownership by 23% to 1,000,556 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/29/25 7:09:34 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Eberwein Jeffrey E. bought $2,999,991 worth of shares (287,631 units at $10.43) and sold $2,999,994 worth of Series A Preferred Stock (320,855 units at $9.35), increasing direct ownership by 15% to 810,217 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/10/25 4:01:17 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    $APTX
    $BIOL
    $DMTK
    $ELOX
    SEC Filings

    View All

    Star Equity Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Star Equity Holdings, Inc. (0001210708) (Filer)

    3/3/26 4:32:00 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    SEC Form 10-K filed by Puma Biotechnology Inc

    10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

    2/26/26 4:41:18 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

    2/26/26 4:16:40 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APTX
    $BIOL
    $DMTK
    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glucotrack to Present at LSI USA '26 Medtech Innovation Summit

    RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer, will present at LSI USA '26 Summit, taking place March 16-20, 2026, in Dana Point, California. The presentation will take place on Tuesday, March 17 at 8:15 a.m. PT. Dr. Goode will introduce Glucotrack's continuous blood glucose monitor (CBGM) technology, share its positive first-in-human study results, outline the Company's regulatory strategy and commercialization

    3/10/26 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

    PRINCETON, N.J., March 10, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the United Kingdom (UK) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of Behçet's Disease. The PIM designation is the first step and a prerequisite towards inclusion in the UK Early

    3/10/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Star Equity Fund Calls on GEE Group to Run a Legitimate Sale Process

    OLD GREENWICH, Conn., March 03, 2026 (GLOBE NEWSWIRE) -- Star Equity Fund, LP ("Star Equity Fund" or "we"), a 5.4% stockholder of GEE Group, Inc. (NYSE:JOB) ("GEE Group" or the "Company"), issues the following statement calling on GEE Group's Board of Directors (the "Board") to immediately retain a qualified, independent investment bank to conduct a thorough and competitive sale process that maximizes value for all GEE Group stockholders. We believe initiating a robust sale process is the most appropriate way for the incumbent board of directors (the "Board") of the Company to exercise its fiduciary duties given the multiple unsolicited offers it said it has received recently. We are call

    3/3/26 8:30:00 AM ET
    $JOB
    $STRR
    Diversified Commercial Services
    Consumer Discretionary
    Professional Services

    $APTX
    $BIOL
    $DMTK
    $ELOX
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $APTX
    $BIOL
    $DMTK
    $ELOX
    Financials

    Live finance-specific insights

    View All

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 million in 2024. Based on accounting principles generally accepted in the United State

    2/26/26 4:05:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutic

    2/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APTX
    $BIOL
    $DMTK
    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    11/12/24 10:32:12 AM ET
    $OMI
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Star Equity Holdings Inc.

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    9/10/24 4:04:39 PM ET
    $STRR
    Professional Services
    Consumer Discretionary